Literature DB >> 18769159

What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator.

Alexander H Stegh1, Lynda Chin, David N Louis, Ronald A DePinho.   

Abstract

Glioblastoma (GBM) is the most common type of primary brain cancer and carries a dismal prognosis primarily due to the emergence of resistance towards extant radiation, conventional and targeted chemotherapies. Although GBM resists therapy-induced apoptosis, tumors show a seemingly paradoxical propensity for florid intratumoral necrogenesis. This necrosis manifests pathologically as microscopic foci or confluent expanses of necrotic tumor. While it is now well recognized that necrosis is an active cell death process and that apoptosis and necrosis death modalities are intertwined on multiple levels, the precise molecular mechanisms and genetic elements underlying these forms of cell death in GBM remain areas of active investigation. In recent oncogenomic studies, we identified a novel GBM oncoprotein, Bcl2-Like 12 (Bcl2L12), which is significantly expressed in the majority of primary GBM tumor specimens and distantly related to canonical Bcl-2 proteins. Due to its distinctive impact on cell death signaling, Bcl2L12 phenocopies pro-necrotic and anti-apoptotic propensities of high grade glioma: Mechanistically, we determined that unlike prototypic Bcl-2 family members, Bcl2L12 does not safeguard mitochondrial membrane integrity, but instead potently inhibits apoptosis at the level of post-mitochondrial effector caspase-3/7 activation. A combination of enforced expression, RNAi-mediated extinction, co-localization and protein interaction studies revealed that Bcl2L12 inhibits caspases 3 and 7 via distinct mechanisms. Direct physical interaction underlies Bcl2L12's inhibition of caspase-7 processing, whereas Bcl2L12-induced transcriptional upregulation of the small heat shock protein alpha B-crystallin is instrumental to neutralization of caspase-3 activation. Mirroring the cellular phenotype elicited by energy depletion, genetic or pharmacologic inhibition of post-mitochondrial apoptosis signaling molecules, Bcl2L12 promotes necrogenesis in glial cells in the context of a proapoptotic stimulus establishing that it represents a novel regulator of the balance between apoptosis and necrosis in GBM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769159     DOI: 10.4161/cc.7.18.6759

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  28 in total

1.  Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.

Authors:  Samuel A Jensen; Emily S Day; Caroline H Ko; Lisa A Hurley; Janina P Luciano; Fotini M Kouri; Timothy J Merkel; Andrea J Luthi; Pinal C Patel; Joshua I Cutler; Weston L Daniel; Alexander W Scott; Matthew W Rotz; Thomas J Meade; David A Giljohann; Chad A Mirkin; Alexander H Stegh
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956

Review 2.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

3.  The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.

Authors:  Sotirios G Papageorgiou; Christos K Kontos; Vassiliki Pappa; Hellinida Thomadaki; Frida Kontsioti; John Dervenoulas; Efstathios Papageorgiou; Theofanis Economopoulos; Andreas Scorilas
Journal:  Oncologist       Date:  2011-07-07

Review 4.  Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.

Authors:  Alexander H Stegh; Ronald A DePinho
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

5.  Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling.

Authors:  Demirkan B Gürsel; Matei A Banu; Nicholas Berry; Roberta Marongiu; Jan-Karl Burkhardt; Keith Kobylarz; Michael G Kaplitt; Shahin Rafii; John A Boockvar
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

6.  Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.

Authors:  Ming-Tsung Lee; Shuk-Mei Ho; Pheruza Tarapore; Irving Chung; Yuet-Kin Leung
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

7.  αB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells.

Authors:  Dorota Goplen; Sébastien Bougnaud; Uros Rajcevic; Stig O Bøe; Kai O Skaftnesmo; Juergen Voges; Per Ø Enger; Jian Wang; Berit B Tysnes; Ole D Laerum; Simone Niclou; Rolf Bjerkvig
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

8.  Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma.

Authors:  Tiffany Doucette; Yuhui Yang; Wei Zhang; Gregory N Fuller; Dima Suki; Daniel W Fults; Ganesh Rao
Journal:  Int J Cancer       Date:  2011-03-04       Impact factor: 7.396

9.  Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor.

Authors:  Alexander H Stegh; Cameron Brennan; John A Mahoney; Kristin L Forloney; Harry T Jenq; Janina P Luciano; Alexei Protopopov; Lynda Chin; Ronald A Depinho
Journal:  Genes Dev       Date:  2010-09-13       Impact factor: 11.361

10.  Cisplatin downregulates BCL2L12, a novel apoptosis-related gene, in glioblastoma cells.

Authors:  Mahdieh Sadat Taghavi; Azim Akbarzadeh; Reza Mahdian; Kayhan Azadmanesh; Gholamreza Javadi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-05-25       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.